{"id":949444,"date":"2026-05-10T01:12:20","date_gmt":"2026-05-10T01:12:20","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/949444\/"},"modified":"2026-05-10T01:12:20","modified_gmt":"2026-05-10T01:12:20","slug":"we-are-not-at-consensus-but-we-are-at-convergence","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/949444\/","title":{"rendered":"‘We are not at consensus but we are at convergence’"},"content":{"rendered":"

Ahead of The Longevity Show, Steve Horvath explains why precision measurement is the first step in a preventative health revolution.<\/strong> <\/p>\n

The Longevity Show<\/a> returns with a program that reflects a field in transition \u2013 no longer content with abstract promises of lifespan extension, but increasingly focused on the practicalities of delivery, measurement and clinical integration. Day two of the Business Conference<\/a>, framed around Engaging With the Future of Longevity, leans into this shift, bringing together clinicians, scientists and operators to explore how emerging tools and technologies are beginning to translate into real-world health optimization. It is a subtle but important recalibration; away from theory and toward implementation, where questions of evidence, scalability and standardization begin to carry more weight than ambition alone.<\/p>\n

Among the sessions, The Science of Assessment<\/a> places measurement firmly at the center of the longevity conversation \u2013 a theme that has gained traction as the field matures. Featuring Principal Investigator at Altos Labs, Dr Steve Horvath, alongside Phil Newman, Dr Raghib Ali and Dr Samantha Decombel, the discussion focuses on biomarkers, multi-omics and evidence-based testing as the foundation for personalized, longitudinal care. Horvath\u2019s presence is particularly notable; as the architect of the epigenetic clock, his work has done more than perhaps any other to shift biological age from abstraction to quantifiable metric, bringing with it both opportunity and a degree of necessary scrutiny.<\/p>\n

Live longer. Live better.\u00a0Live now.<\/strong>
Step into the future of healthy\u00a0longevity at The\u00a0Longevity\u00a0Show \u2013 LT readers receive 20% off with code LT20.<\/strong> <\/p>\n

Longevity.Technology: If longevity medicine is to move beyond well-intentioned optimization into something resembling a clinical discipline, it will need to answer a deceptively simple question: how do we measure it? Sessions such as this suggest the field is beginning to take that challenge seriously \u2013 not through any single biomarker or platform, but through a layered approach that combines molecular data, longitudinal tracking and increasingly sophisticated interpretation. Horvath\u2019s contribution sits at the heart of that evolution; his epigenetic clocks have become both a tool and a loaded gauntlet, forcing the sector to confront what biological age actually represents and how confidently it can be acted upon. Around this, a broader ecosystem is emerging \u2013 multi-omics panels, AI-driven analytics, clinical protocols \u2013 each promising clarity, each introducing its own complexity. The risk, perhaps, is that measurement outpaces meaning, that data accumulates faster than consensus. Yet without such efforts, longevity remains descriptive rather than actionable. In that sense, the real significance of sessions like this lies not in any single insight, but in the attempt to build a coherent diagnostic framework \u2013 one capable of translating biological signals into decisions, interventions and, ultimately, outcomes that can be tracked over time. Leading up to The Longevity Show, we sat down with Dr Steve Horvath to discuss the biological reality of epigenetic timing and the necessity of clinical unity.<\/strong><\/strong><\/p>\n

Riding more than the first wave<\/strong> <\/p>\n

For all the proliferation of biological age clocks \u2013 and the inevitable confusion that has followed \u2013 Horvath is clear that the field is not as fragmented as it might appear. \u201cWe are not at consensus but we are at convergence,\u201d he tells us, pointing to a gradual alignment around a smaller number of validated tools.<\/p>\n

The early generation of clocks, trained against chronological age, served a purpose but were never designed with clinical translation in mind. \u201cThe first wave of clocks was trained against chronological age which is useful for certain applications but limited when it comes to human clinical trials,\u201d he explains. More recent iterations \u2013 including PhenoAge and GrimAge \u2013 have shifted toward phenotypic and mortality-linked outcomes, while DunedinPACE attempts to quantify the rate at which an individual is aging.<\/p>\n

This evolution is beginning to crystallise into something more structured. Horvath describes an emerging set of criteria that any clinically meaningful biomarker must meet: \u201cit has to predict hard outcomes such as time to death or specific diseases, it has to move in response to interventions, and it has to replicate across populations.\u201d The direction of travel is encouraging, even if the destination remains just out of reach. \u201cWe are much closer to that bar than we were five years ago but harmonization of assays and prospective interventional data are still works in progress. Almost there.\u201d<\/p>\n

\"\"The Longevity Show Business Conference is set to draw a global crowd, including researchers, clinicians, scientists, founders and investors A moment of alignment<\/strong> <\/p>\n

If the science is converging, so too is the broader ecosystem around it \u2013 which, in Horvath\u2019s view, helps explain why events like The Longevity Show are emerging with a more practical, translational focus.<\/p>\n

\u201cSeveral things have aligned,\u201d he says. \u201cThe geroscience hypothesis, i.e. that targeting aging biology itself is a tractable strategy, is no longer fringe.\u201d That shift has been accompanied by more tangible progress: surrogate endpoints that avoid the need for decades-long mortality studies, early human trials beginning to report results, and a growing influx of capital from both established players and newer longevity-focused ventures.<\/p>\n

Then there is the demographic backdrop \u2013 impossible to ignore and increasingly difficult to defer. \u201cAging populations across most of the developed world,\u201d Horvath notes, have turned longevity from an intellectual curiosity into something closer to a policy and economic imperative. \u201cSlowing or reversing aging has arguably become an economic and medical priority not a niche curiosity.\u201d<\/p>\n

Still, he offers a note of restraint \u2013 or perhaps realism. \u201cThe honest counterweight is that there is a lot of wishful thinking as opposed to hard data,\u201d he says, expressing a hope that forums like this can \u201chelp to separate signal from hype.\u201d<\/p>\n

The limits of precision<\/strong> <\/p>\n

If measurement is becoming more sophisticated, it is also becoming more nuanced \u2013 and, in some respects, more complicated. The idea of a single, definitive biological age readout remains appealing, but Horvath is quick to challenge the premise.<\/p>\n

\u201cI think the premise needs a correction first: we cannot yet measure biological age with total precision,\u201d he says. Nor, he suggests, is that ever likely to be possible through a single metric. \u201cBiological age is multi-dimensional. The full picture comes from a basket of measurements.\u201d<\/p>\n

That basket is expansive; biochemical blood panels, methylation data, proteomics and metabolomics sit alongside imaging, wearable-derived data and functional assessments such as VO2 max, muscle strength and cognitive performance. Each captures a different facet of aging biology, and none can stand entirely alone.<\/p>\n

The question of how individuals engage with this data is equally complex. For some, the act of measurement is inherently motivating. \u201cSome people genuinely enjoy measurement. I am one of them,\u201d Horvath admits. \u201cI treat it as a hobby and it motivates me to maintain a healthy lifestyle.\u201d Others, however, may find the same information overwhelming or anxiety-inducing. \u201cToo much testing makes them anxious. I respect that.\u201d<\/p>\n

His advice, characteristically, lands somewhere in the middle. \u201cThere is a sensible middle ground. Get your blood pressure and standard vitals checked roughly once a year. Pay attention to the basics. But do not obsess unless you are a longevity athlete.\u201d The deeper point, though, is less technical and more human. \u201cYour happiness and purpose are not built out of test results. It\u2019s built out of friendships, purpose, making time for fun, good sleep, and movement. Tests are a useful nudge at least to me but they are not the destination.\u201d<\/p>\n

Beyond the clock<\/strong> <\/p>\n

For someone whose work helped define the field, Horvath is notably forward-looking about what comes next. The concept of a single, whole-body clock may ultimately give way to something far more granular.<\/p>\n

\u201cThe most important [frontier] is moving from whole-body, blood-based clocks to clocks that accurately measure the biological age of individual organs and organ systems,\u201d he says, pointing to the brain, kidney, lung, liver and heart as obvious candidates. Such resolution would allow clinicians to identify which systems are aging fastest within a given individual \u2013 and intervene before dysfunction becomes clinically apparent.<\/p>\n

This, in turn, opens up a more fundamental question. \u201cCan we find targeted interventions\u2026 that reverse damage or rejuvenate an organ before it fails?\u201d If the answer is yes, the implications extend well beyond individual health. \u201cWe change the entire economics of medicine, because prevention is dramatically cheaper than treatment. A stitch in time saves nine.\u201d<\/p>\n

For researchers, the horizon stretches further still, toward increasingly fine-grained models of aging. Horvath points to \u201csingle cell aging clocks in different species\u201d as another emerging area \u2013 a reminder that, even as the field edges closer to clinical application, its scientific foundations continue to evolve.<\/p>\n

The Longevity Show \u2013 a festival of science, wellness & human potential<\/strong>
26 \u2013 27 June 2026 | Tobacco Dock, London<\/strong> <\/p>\n","protected":false},"excerpt":{"rendered":"Ahead of The Longevity Show, Steve Horvath explains why precision measurement is the first step in a preventative…\n","protected":false},"author":2,"featured_media":949445,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4316],"tags":[264883,264884,920,105,4348,264885,462,257,209070,264886,16,15],"class_list":{"0":"post-949444","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-aging-clocks","9":"tag-altos-labs","10":"tag-events","11":"tag-health","12":"tag-healthcare","13":"tag-horvath-clock","14":"tag-interview","15":"tag-london","16":"tag-longevity-show","17":"tag-steve-horvath","18":"tag-uk","19":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116547626297659752","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/949444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=949444"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/949444\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/949445"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=949444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=949444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=949444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}